SRC and hepatocellular carcinoma: Owing to the crucial role of Src signaling in the pathogenic events of HCC, including proliferation, invasion, angiogenesis, and drug resistance, the United States Food and Drug Administration (FDA) has approved saracatinib, an Src inhibitor, as the first targeted therapy for the treatment of HCC [32].